PRCT - Procept BioRobotics Corp Dividends
This article provides a detailed financial overview of Procept BioRobotics Corp (PRCT), including its latest stock performance, key financial metrics, and insider transaction data. It highlights the company's current stock price, recent percentage change, market capitalization, and various profitability ratios. The report also lists sales growth, EPS trends, and institutional ownership, but notes the absence of dividend information.
Truist Securities downgraded the stock rating of PROCEPT BioRobotics Corp from "Buy" to "Hold"
Truist Securities has downgraded PROCEPT BioRobotics Corp's stock rating from "Buy" to "Hold" and significantly reduced its target share price from $30 to $25. This decision reflects a re-evaluation by the institution regarding the company's investment prospects. The article also includes a disclaimer that its content represents only the author's opinion and is not investment advice.
If You Invested $1,000 in Procept Biorobotics Corp (PRCT)
This article analyzes the historical performance of Procept Biorobotics Corp (PRCT) stock, detailing how a $1,000 investment would have fared over different periods. It also provides an overview of the company's focus on surgical robotics for urology, specifically its AQUABEAM and HYDROS Robotic Systems for Aquablation therapy, and highlights its clinical evidence, market context, and recent regulatory developments.
Truist cuts Procept BioRobotics stock rating on reimbursement concerns
Truist Securities downgraded Procept BioRobotics Corp (NASDAQ:PRCT) to Hold from Buy and lowered its price target due to concerns over reimbursement for its Aquablation procedures. This downgrade follows a proposal from the Centers for Medicare and Medicaid Services to increase reimbursement for a competing procedure, prostate artery embolization, which Truist believes will further enhance its profit incentive over Aquablation, despite questions about its efficacy. The firm also expressed reduced confidence in Procept BioRobotics’ revenue growth reacceleration prospects and cut its 2026-2027 revenue estimates.
PROCEPT BioRobotics (PRCT) Is Up 7.2% After WATER IV Milestones Spotlight Aquablation’s Oncology Potential – Has The Bull Case Changed?
PROCEPT BioRobotics (PRCT) saw its stock rise by 7.2% following milestones in its WATER IV prostate cancer trials, suggesting Aquablation therapy could expand into urologic oncology. This development could broaden the company's market beyond benign prostatic hyperplasia, reinforcing its long-term growth potential. While these clinical advancements are promising, investors are advised to consider the ongoing risk of operating losses and heavy R&D investment.
Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential
Evercore ISI has initiated coverage on PROCEPT BioRobotics (PRCT) with an "Outperform" rating and a $30 price target, highlighting the potential of Aquablation therapy. The company recently achieved two significant milestones in its WATER IV prostate cancer clinical program, including the completion of enrollment for a randomized trial and FDA IDE approval for a second protocol, which could expand its addressable market into prostate cancer. Analyst Vijay Kumar believes a positive trial outcome could also lead to multiple expansion for the stock.
Price to earnings forward of PROCEPT BioRobotics Corp. – BX:PRCT
This article provides financial data for PROCEPT BioRobotics Corp. (BX:PRCT), specifically focusing on its price-to-earnings forward metric. The content highlights the period, value, and change percentage of this financial indicator, noting that the data is provided by ICE Data Services and FactSet Research Systems Inc.
Price to sales forward of PROCEPT BioRobotics Corp. – BX:PRCT
This article provides the "Price to sales forward" financial metric for PROCEPT BioRobotics Corp. (BX:PRCT) on the TradingView platform. It shows the company's ticker, exchange, and confirms that the market is currently closed with no trades. The data presented is stated as being "Made by humans."
PRCT Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for PROCEPT BioRobotics Corp. (PRCT) stock, based on analyst opinions. It highlights the current stock price, market capitalization, volatility, and details on past earnings, revenue, and upcoming earnings reports. Additionally, it answers frequently asked questions about PRCT stock performance and financial metrics.
Price to book forward of PROCEPT BioRobotics Corp. – BX:PRCT
This page displays the "Price to book forward" financial metric for PROCEPT BioRobotics Corp. (PRCT) on the BX Swiss exchange. It indicates that the financial data is 'Made by humans' and sources its market and reference data from ICE Data Services and FactSet, respectively. The page is minimalistic, focusing solely on this specific financial indicator without additional analysis or commentary.
Evercore ISI initiates Procept BioRobotics stock with outperform rating
Evercore ISI initiated coverage on Procept BioRobotics (NASDAQ:PRCT) with an outperform rating and a $30 price target, highlighting the company's strong long-term fundamentals despite short-term challenges. The firm believes Procept's Aquablation technology has superior clinical evidence and a positive outcome from the WATER IV trial could expand its market to prostate cancer. This initiation comes as PRCT trades near its 52-week low, and InvestingPro analysis suggests the stock is undervalued, aligning with Evercore's target.
Evercore ISI initiates Procept BioRobotics stock with outperform rating
Evercore ISI has initiated coverage on Procept BioRobotics Corp (NASDAQ:PRCT) with an outperform rating and a $30 price target, citing the company's strong long-term fundamentals and innovative Aquablation technology. This target suggests a 36% upside from current levels, though the stock is near its 52-week low. The firm highlights the potential expansion of the total addressable market with positive WATER IV trial results and notes Procept's strong revenue growth and healthy cash position, despite not yet being profitable.
Evercore ISI initiates Procept BioRobotics stock with outperform rating By Investing.com
Evercore ISI has initiated coverage on Procept BioRobotics (NASDAQ:PRCT) with an outperform rating and a $30.00 price target, citing the company's strong long-term fundamentals despite short-term challenges. The firm believes Procept's Aquablation technology has superior clinical evidence and a potential market expansion into prostate cancer with positive WATER IV trial results. This positive outlook is supported by InvestingPro analysis, which deems PRCT undervalued, aligning with Evercore's target, even though the company is currently unprofitable.
5 Best Robotics and Automation Stocks to Invest In
This article lists the top 5 robotics and automation stocks to consider for investment, highlighting PROCEPT BioRobotics Corp. as one of them. PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is praised for its advancements in prostate cancer treatment with its Aquablation therapy, particularly its ongoing WATER IV clinical trials. The article provides details on the company's FDA approvals and patient enrollment milestones, emphasizing its commitment to innovation in male urological health despite a recent downgrade by Leerink.
PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20
Bank of America has downgraded PROCEPT BioRobotics (PRCT) to 'Underperform' from 'Neutral' and cut its price target to $20 from $38, following the company's Q4 results which missed street estimates. Concerns were raised about earnings visibility, profitability, and execution, as Q4 revenue of $76.4 million and a loss per share of $0.53 fell short of forecasts. Despite the analyst downgrade and a significant pre-market stock tumble, retail investor sentiment on Stocktwits shifted to 'extremely bullish'.
PROCEPT BioRobotics (PRCT) Is Down 6.5% After Institutional Ownership Surges Past Shares Outstanding Has The Bull Case Changed?
PROCEPT BioRobotics (PRCT) has experienced a 6.5% stock drop despite strong year-over-year revenue and net profit growth, coupled with a surge in institutional ownership exceeding total shares outstanding. The company's investment narrative centers on Aquablation becoming a standard in urologic care, with potential expansion into prostate cancer, though it still faces ongoing losses and execution risks. Investors are advised to consider the mixed technical signals and the gap between current valuations and analyst forecasts, which suggest a significant upside potential for PRCT.
PROCEPT BioRobotics (PRCT) Stock Could Be 14% Undervalued After Growth Outlook Holds
Despite a recent stock decline, PROCEPT BioRobotics (PRCT) is considered 14% undervalued with a fair value of $25.26 per share, even though it currently trades at $21.72. Analyst commentary highlights rapid revenue growth, expanding gross margins, and lower management guidance. According to the CEO, recent downgrades based on potential headwinds like PAE are unfounded, suggesting the stock is oversold and poised for recovery if Q2 numbers are met.
Top 3 Health Care Stocks You'll Regret Missing In Q2
This article identifies three oversold health care stocks—iRhythm Holdings, Anbio Biotechnology, and Procept Biorobotics—that investors might regret missing in Q2. These companies are highlighted based on their Relative Strength Index (RSI) being near or below 30, indicating a potential undervaluation and an opportunity for short-term gains. Each stock's recent price action and relevant news, such as downgrades or cybersecurity incidents, are discussed.
Procept Biorobotics Corp (PRCT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Procept Biorobotics Corp (PRCT), listing its major institutional holders like Fidelity Management & Research Company LLC, BlackRock, and AllianceBernstein. It provides a breakdown of shareholder types, institutional shareholding trends over various quarters, and recent changes in holdings by key institutions. The report also lists ETFs that include PRCT shares.
Procept Biorobotics Corp (PRCT) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Procept Biorobotics Corp (PRCT), detailing its current earnings forecast score, analyst ratings, and price targets. PRCT ranks 142 out of 203 in the Healthcare Equipment & Supplies industry with a "Buy" trend based on 15 analysts, and is expected to have a revenue of $93.06 million for the next quarter. The average price target is $51.00, with a high of $75.00 and a low of $38.00.
Procept Biorobotics Corp (PRCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Procept Biorobotics Corp (PRCT) as of April 6, 2025. It categorizes the company's revenue by business segments, including hand pieces and other consumables, system sales and rentals, and service. Additionally, it shows the regional revenue distribution between the United States and outside the United States.
Leerink downgrades Procept BioRobotics stock rating on competition
Leerink downgraded Procept BioRobotics Corp (NASDAQ:PRCT) to Market Perform from Outperform, lowering its price target to $29 due to increased competition from prostate artery embolization. Despite the downgrade, InvestingPro analysis suggests the company is undervalued, with a fair value of $32.31. Procept BioRobotics recently reported strong Q1 2026 earnings and made significant progress in clinical trials for Aquablation therapy.
Leerink downgrades Procept BioRobotics stock rating on competition
Leerink downgraded Procept BioRobotics Corp (NASDAQ:PRCT) to Market Perform from Outperform, lowering its price target to $29 from $31, citing increased competition from prostate artery embolization. Despite the downgrade, InvestingPro analysis suggests the company is undervalued, with a fair value of $32.31, and it maintains a strong balance sheet although it has been unprofitable over the past year. This decision was influenced by discussions with key opinion leaders, and comes despite the company's recent strong Q1 2026 earnings and progress in its clinical trials for prostate cancer treatment.
Director Frederic Moll of PROCEPT BioRobotics (PRCT) granted RSUs and options
PROCEPT BioRobotics director Frederic H. Moll received equity awards, including 3,315 restricted stock units and a stock option for 5,853 shares with an exercise price of $28.78. These grants are part of his routine compensation and will vest on the earlier of one year from the grant date or the next annual meeting, subject to continued service. Following these awards, Moll directly holds 866,474 shares of common stock, indicating these are compensation-related grants rather than open-market transactions.
[Form 4] PROCEPT BioRobotics Corp Insider Trading Activity
PROCEPT BioRobotics Corp (PRCT) director Thomas M. Prescott was granted 3,315 restricted stock units (RSUs) and stock options for 5,853 shares, serving as compensation awards rather than open-market transactions. The RSUs and options vest fully on the earlier of one year from the June 9, 2026 grant date or the next annual meeting, provided Prescott continues his service. After these awards, Prescott holds 7,211 shares of Common Stock, and the stock options have an exercise price of $28.78 per share, expiring on June 8, 2036.
PROCEPT BioRobotics (PRCT) director receives RSU and option grants as equity pay
PROCEPT BioRobotics director Antal Rohit Desai received new equity compensation, including 3,315 restricted stock units (RSUs) and a stock option for 5,853 shares with an exercise price of $28.78. These grants are part of his routine board compensation and will vest fully on the earlier of one year from the June 9, 2026 grant date or the next annual meeting, subject to his continued service. Following these transactions, Desai's reported holdings include 38,467 shares of Common Stock and the new stock option.
Procept BioRobotics EVP Nouri Alaleh sells $8,116 in stock
Nouri Alaleh, EVP, Chief Legal Officer, and Corporate Secretary at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 285 shares of company stock worth $8,116. This transaction was part of a sell-to-cover process for tax obligations related to RSU vesting. Following the sale, Alaleh still holds 105,069 shares, and the company has recently shown strong financial performance and is advancing a prostate cancer clinical program.
Director at PROCEPT BioRobotics (PRCT) receives new RSU and option awards
PROCEPT BioRobotics (PRCT) director Taylor C. Harris was granted 3,315 restricted stock units (RSUs) and 5,853 stock options with an exercise price of $28.78 per share. These equity awards, part of his director compensation, will vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting, subject to continued service. Following this transaction, Harris directly holds 102,491 shares of Common Stock.
PROCEPT BioRobotics (PRCT) director Mary Garrett granted RSUs and options
PROCEPT BioRobotics director Mary Garrett received new equity awards, including 3,315 restricted stock units (RSUs) and a stock option for 5,853 shares with an exercise price of $28.78. Following these grants, her direct common stock holdings now total 17,700 shares. Both the RSUs and the stock option are set to vest one year from the June 9, 2026 grant date or at the next annual meeting, provided she continues her service.
Director at PROCEPT (PRCT) granted RSUs and stock options
PROCEPT BioRobotics director Dan Puckett received new equity awards comprising 3,315 restricted stock units (RSUs) and stock options for 5,853 shares, with an exercise price of $28.78 per share and an expiration date of June 8, 2036. Following the grant, his direct common stock holdings increased to 8,791 shares. Both the RSUs and options vest in full on the earlier of one year from the June 9, 2026 grant date or the next annual meeting, contingent on his continued service.
Director at PROCEPT BioRobotics (PRCT) receives RSU and stock option grants
PROCEPT BioRobotics director Elisabeth Sandoval was granted 3,315 restricted stock units (RSUs) and stock options for 5,853 shares with an exercise price of $28.78 per share on June 9, 2026. Both the RSUs and options will vest in full on the earlier of one year from the grant date or the company's next annual meeting, contingent on her continued service. After these grants, Sandoval directly owns 15,876 shares of common stock, and the new options are set to expire on June 8, 2036.
[8-K] PROCEPT BioRobotics Corp Reports Material Event
PROCEPT BioRobotics (NASDAQ: PRCT) filed an 8-K report detailing the results of its annual stockholder meeting held on June 9, 2026. Stockholders elected three directors, ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026, and approved the compensation of named executive officers on a non-binding advisory basis. The filing provided specific vote counts for each proposal.
[Form 4] PROCEPT BioRobotics Corp Insider Trading Activity
PROCEPT BioRobotics Corp's EVP and Chief Legal Officer, Nouri Alaleh, sold 285 shares of common stock at $28.48 per share. This sale was a "sell-to-cover" transaction to satisfy tax obligations related to vested restricted stock units, and represents a minor portion of Alaleh's total holdings of 105,069 shares. The transaction is deemed routine and has a neutral impact and sentiment according to analysts.
PROCEPT BioRobotics (PRCT) Is Up 5.7% After New WATER IV Trials Expand Aquablation Testing Scope
PROCEPT BioRobotics (PRCT) saw its stock rise by 5.7% following new milestones in its WATER IV prostate cancer program. The company fully enrolled a 280-patient trial comparing Aquablation therapy with radical prostatectomy and received FDA IDE approval for a second study comparing Aquablation with active surveillance. These developments aim to expand treatment options for prostate cancer and strengthen the long-term clinical narrative for PROCEPT BioRobotics, although the company still faces challenges with ongoing losses, high valuation, and market competition.
PRCT (NASDAQ) Rule 144 notice: Director activity, 357 vested shares reported
PROCEPT BioRobotics Corp (PRCT) has filed a Rule 144 notice for the proposed sale of 357 common stock shares, which vested on June 5, 2026, with an associated value of $10,167.00. The filing also indicates previous activity by Kevin Waters, who sold 706 shares on March 17, 2026, for $19,876.16. This notice relates to restricted stock vesting as compensation.
PRCT (NASDAQ) insider sale notice — 358 vested shares to be sold
PROCEPT BioRobotics Corp (PRCT) has filed a Form 144 indicating an insider's intent to sell 358 vested shares originating from restricted stock vesting on June 5, 2026. The filing also notes a previous sale of 882 shares on March 17, 2026, by Barry L. Templin. This is described as a routine post-vesting disposition rather than a change in company strategy.
PROCEPT BioRobotics (PRCT) Is Down 9.2% After Aquablation WATER IV Milestones - What's Changed
PROCEPT BioRobotics (PRCT) recently achieved two major milestones in its WATER IV prostate cancer program, completing enrollment for a trial comparing Aquablation therapy with radical prostatectomy and securing FDA IDE approval for a second study against active surveillance. These trials aim to position Aquablation as an alternative to both surgery and watchful waiting. Despite these advancements, the company still faces challenges related to controlling losses and ensuring rapid adoption of its technology and new HYDROS robotic system, as its investment narrative focuses on sustained procedure and system growth.
PRCT - Procept BioRobotics Corp Stock Price and Quote
This article provides a detailed financial overview and news compilation for Procept BioRobotics Corp (PRCT). It includes key financial metrics, stock performance data, analyst ratings, and a chronological list of recent new headlines affecting the company. The content also features insider trading information for several executives and directors.
PROCEPT BioRobotics (PRCT) Is Down 9.2% After Aquablation WATER IV Milestones - What's Changed
PROCEPT BioRobotics (PRCT) announced two major milestones in its WATER IV prostate cancer program, completing enrollment in a randomized trial comparing Aquablation therapy with radical prostatectomy and securing FDA IDE approval for a second randomized study against active surveillance. These trials aim to position Aquablation as an alternative to surgery and watchful waiting. Despite these advances, the company's stock fell by 9.2%, and investors are still focused on increasing utilization of the installed base and PROCEPT's ability to control losses as it scales.
PROCEPT BioRobotics (PRCT) Is Down 6.0% After WATER IV Trial Milestones – Has The Bull Case Changed?
PROCEPT BioRobotics (PRCT) recently achieved two milestones in its WATER IV prostate cancer program, completing enrollment in a randomized trial and securing FDA IDE approval for another. These trials aim to evaluate Aquablation against surgery and watchful waiting for cancer control and quality-of-life outcomes. While these are important clinical developments, the company's investment narrative still relies on Aquablation becoming a core urology platform with sustained revenue growth, despite ongoing losses and market pressures.
Procept secures FDA IDE for Aquablation and completes WATER IV study enrolment
Procept BioRobotics has received a second FDA investigational device exemption (IDE) for its Aquablation therapy, allowing a new randomized study comparing it to active surveillance for prostate cancer. The company has also completed enrollment for its WATER IV study, which compares Aquablation to radical prostatectomy, and expects primary endpoint results in 2027. Both WATER IV protocols will monitor disease control and quality of life outcomes over ten years.
Procept BioRobotics completes enrollment in prostate cancer study
PROCEPT BioRobotics has completed enrollment in its WATER IV randomized study comparing Aquablation therapy to radical prostatectomy for prostate cancer and received FDA approval for a second randomized study. The company expects to present primary endpoint results for the first study in spring 2027. Despite strong revenue growth and gross profit margin, the company remains unprofitable, though it recently exceeded EPS and revenue expectations for Q1 2026.
Only FDA randomized study tests robotic waterjet prostate surgery vs removal
PROCEPT BioRobotics (PRCT) announced the completion of enrollment for its WATER IV RP randomized study, which compares Aquablation therapy to radical prostatectomy for prostate cancer. Concurrently, the company received FDA IDE approval for a second randomized protocol, WATER IV AS, evaluating Aquablation therapy against active surveillance for men with lower-risk prostate cancer. Both studies involve ten-year patient follow-ups, assessing disease control and quality-of-life outcomes, with primary endpoint results for WATER IV RP expected in spring 2027.
A Look At PROCEPT BioRobotics (PRCT) Valuation After Its Better Than Expected Q1 Earnings And Analyst Updates
PROCEPT BioRobotics (PRCT) received increased attention after reporting better-than-expected Q1 results, leading to a stock price jump and updated analyst views. Despite recent short-term gains, the longer-term share price performance has been weak. Analysts currently see PRCT as undervalued with a fair value of $30.44 based on future Aquablation adoption, though its current P/S ratio is higher than the industry average, posing a valuation risk.
Here’s What the Street Thinks About PROCEPT BioRobotics Corporation (PRCT)
PROCEPT BioRobotics Corporation (PRCT) recently received updated ratings from Piper Sandler and Baird following its strong fiscal Q1 results, which exceeded top-line expectations and led to a reiterated full-year guidance. Piper Sandler raised its price target to $35 with an "Overweight" rating, recognizing impressive capital placements. Baird also increased its price target to $28 but maintained a "Neutral" rating, citing cautious long-term adoption despite the positive quarterly performance.
Lisanti Capital Growth LLC Buys Shares of 35,890 PROCEPT BioRobotics Corporation $PRCT
Lisanti Capital Growth LLC recently acquired 35,890 shares of PROCEPT BioRobotics Corporation, marking a new position valued at approximately $1.13 million. This purchase contributes to the already high institutional ownership of 89.46% in PROCEPT BioRobotics. The company recorded a 20.1% increase in revenue to $83.13 million but slightly missed EPS expectations at -$0.56.
DNB Asset Management AS Has $3.13 Million Stock Position in PROCEPT BioRobotics Corporation $PRCT
DNB Asset Management AS significantly increased its stake in PROCEPT BioRobotics Corporation by 213.9% in Q4, holding 99,567 shares valued at $3.13 million. Wall Street analysts maintain a "Hold" consensus rating with an average target price of $41.45, despite the company reporting strong Q1 revenue growth of 20.1% to $83.13 million, exceeding estimates. Insider activity shows mixed signals, with an executive selling shares while a director made a substantial purchase.
AllianceBernstein (PRCT) discloses 147,327 shares; 0.3% stake reported
AllianceBernstein L.P. has amended its Schedule 13G to report beneficial ownership of 147,327 shares of PROCEPT BioRobotics Corp Common Stock, representing a 0.3% stake. These shares are held in discretionary client accounts, with AllianceBernstein having sole voting power over 146,027 shares and sole dispositive power over all 147,327 shares. The filing, signed on May 15, 2026, indicates a passive investment and clarifies AllianceBernstein's independent management from its majority owner, Equitable Holdings, Inc.
A Look At PROCEPT BioRobotics (PRCT) Valuation As AUA Guideline Update Expands Aquablation Opportunity
PROCEPT BioRobotics (PRCT) is gaining attention after updated AUA guidelines supported its Aquablation therapy for BPH, including larger prostates. Despite a recent 2.83% share price increase, the stock is down 55.02% over the past year, trading 16.6% below the average analyst target. The most common valuation narrative suggests an undervalued price of $30.44 per share, contingent on continued procedure adoption and margin expansion.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Average Recommendation of "Hold" from Brokerages
PROCEPT BioRobotics (NASDAQ:PRCT) has received a consensus "Hold" rating from 14 research firms, with an average 1-year price target of $41.45. The company recently reported Q1 revenue of $83.13 million, exceeding estimates, though EPS was slightly worse than expected at -$0.56. Insider activity showed mixed signals, with a director purchasing shares and an EVP selling some, while institutional ownership remains high.
